🔗 Share this article

Government ministers and leading parliamentarians have issued warnings that the United Kingdom's negotiated accords with Donald Trump are "fundamentally unstable." This stems from revelations that a recently announced deal on drug pricing, which pledges zero tariffs in exchange for the NHS paying more, lacks any formal legal text beyond vague headline terms contained within government press releases.

An Agreement in Principle Only

The arrangement concerning medicines, promoted as a "generational" achievement, remains an "agreement in principle" without a signed legal text. It has been highlighted that the official announcements from the UK and US governments present the deal in markedly contrasting terms. The British version focuses on securing "duty-free access" as a singular success, while the American announcement highlights the agreement for the NHS to pay significantly more for new medications.

"We face a genuine possibility that the UK government has agreed to terms to raise drug prices in return for nothing more than a verbal promise from President Trump," stated David Henig, a trade expert. "We know he has form for not following through on agreements."

Wider Concerns Amidst a Suspended Agreement

Worries have been amplified by Washington's recent decision to put on ice the £31bn "tech prosperity deal", which was previously heralded as "a huge leap forward" in the bilateral relationship. The US claimed a failure to advance from the UK on lowering trade barriers as the reason for the pause.

In a separate development, concessions agreed to for British farmers as part of an earlier tariff deal have yet to be formally approved by the US, despite a imminent January deadline. "Our understanding is that the US has not finalized the agreed beef export quotas," said Tom Bradshaw of the National Farmers' Union.

Private Ministerial Concerns

In confidential discussions, ministers have voiced worries that the government's agreements with the US are lacking substance. One minister reportedly said the series of agreements as "resting on shaky ground," while another described the situation as the "current reality" in the transatlantic relationship, marked by "additional layers of volatility and unpredictability."

Layla Moran, a senior MP on the health committee, stated: "The only thing more surprising than Trump's temper tantrums is the UK government's optimistic assumption that his administration is a good faith actor. The NHS is not a bargaining chip."

Government Downplays Risks, Points to Gains

Government figures have downplayed the possibility of the US reneging on the pharmaceuticals deal. One source noted the US pharmaceutical industry itself had been lobbying for the agreement, desiring stability on imports and pricing, making it of tangible value than the paused tech deal.

Officials admit that instability is inherent in dealing with the current US leadership. However, they contend that the UK has achieved real benefits for businesses, such as lower steel tariffs compared to other nations. "Securing 25% steel tariffs, which is lower than the rate for the rest of the world, is not flimsy," one official said.

Yet, problems have emerged in enacting the initial US-UK accord. Promised reciprocal agricultural allowances have not materialized, and the pledge to "reduce steel tariffs to zero" has not been fulfilled, with tariffs remaining at 25%.

Looking ahead, the two sides have planned to recommence talks on the suspended digital agreement in January, following what were described as "constructive" meetings between UK and US officials in Washington.